RA
PBE icon

RFG Advisory’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

RFG Advisory’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763K Hold
8,510
– – 0.01% 670
2026
Q1 		$674K Buy
8,510
+55
+0.7% +$4.45K 0.01% 655
2025
Q4 		$695K Buy
8,455
+521
+7% +$40.3K 0.01% 614
2025
Q3 		$554K Buy
7,934
+3,250
+69% +$220K 0.01% 637
2025
Q2 		$300K Buy
+4,684
New +$290K 0.01% 774

Other funds holding PBE

YIA
YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return
DAS
Dynamic Advisor Solutions Phoenix, Arizona $3.53B AUM 22.61% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

RFG Advisory's PBE Position: Q2 2026 in Review

RFG Advisory held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q2 2026 at 8,510 shares worth $763K. The position accounts for 0.01% of the portfolio, ranked #670.

RFG Advisory first reported a position in PBE in Q2 2025 and has held it in 5 quarters since. 9 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

  • RFG Advisory held 8,510 shares of Invesco Biotechnology & Genome ETF worth $763K as of Q2 2026.
  • RFG Advisory left its Invesco Biotechnology & Genome ETF share count unchanged in Q2 2026.
  • Invesco Biotechnology & Genome ETF made up 0.01% of RFG Advisory's portfolio in Q2 2026, its #670 holding.
  • RFG Advisory first reported a position in Invesco Biotechnology & Genome ETF in Q2 2025 and has held it in 5 quarters since.
  • 9 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.